Comparative Pharmacology
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE versus OSMOVIST 190.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE versus OSMOVIST 190.
DIATRIZOATE MEGLUMINE vs OSMOVIST 190
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diatrizoate meglumine is an ionic, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, thereby enhancing radiographic imaging. It does not exert pharmacological effects via receptor interaction but functions by attenuating X-ray beams, providing contrast between vascular structures and surrounding tissues.
Iodinated contrast media with high osmolality, providing radiographic contrast by attenuating X-rays, primarily due to iodine content.
Intravenous: 1-2 mL/kg (305-610 mg I/kg) of 60% or 76% solution for urography; 40-60 mL of 50% solution for retrograde cystourethrography. Oral: 200-600 mL of 4.8% suspension for GI contrast.
Intravenous administration of 0.1-0.3 mL/kg (0.19-0.57 mg iodine/kg) for adults; may repeat as needed. Maximum total dose 1.5 mL/kg.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function (CLcr >90 mL/min). Half-life is significantly prolonged in renal impairment (up to 20-40 hours in anuria), necessitating dose adjustment and caution.
Terminal elimination half-life approximately 110 minutes. In renal impairment, half-life is prolonged, requiring dose adjustment.
Primarily renal excretion via glomerular filtration; >95% of the administered dose is excreted unchanged in urine within 24 hours. Less than 5% is excreted in feces via biliary elimination.
Primarily renal (glomerular filtration). Excreted unchanged in urine, with less than 2% biliary/fecal excretion.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent